Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Moderate-to-severe Atopic Dermatitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ICP-332 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

20 Aug 2024 Results presented in an Innocare media release.
11 Jun 2024 According to an Innocare media release, data from this trial was presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral presentation.
17 Dec 2023 Primary endpoint (Percentage change of EASI score from baseline in week 4) has been met, according to an Innocare media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com